NCT07159763ClinicalTrials.gov
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
En bref
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza…
Phase 310 000 participants recherchés211 sites6 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07159763Ouvrir cette fiche sur ClinicalTrials.govSynchronisé avant-hier
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-09-08; recorded start 2025-09-25
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA))
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 181 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A very large study, international in scope: 10,000 participants (target), run at 211 sites, across 6 countries.
How this score is built
- Enrolment38/40
10,000 participants (target)
- Site count25/25
181 sites
- Country count7/15
5 countries
- Planned duration6/10
Planned over about 20 months
- Sponsor scale2/10
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has led 4 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406 (CD388) can help prevent the flu in people who are at higher risk of becoming seriously ill from influenza. Researchers want to find out if MK-1406 dosed at a single study visit can provide protection against influenza compared with placebo. The study will include adolescents and adults who may be more vulnerable to complications from influenza because of their age, health conditions, or weakened immune systems. Researchers will also evaluate the safety of MK-1406 and how well participants tolerate the study medicine.
Affections
- Influenza
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 12 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 3 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | PREVENTION |
| Insu | QUADRUPLE (4) |
| Recrutement | 10 000 participants recherchés |
Promoteur et collaborateurs
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Promoteur
Groupes et interventions
- MK-1406EXPERIMENTAL
Participants will receive 450 milligrams (mg) dose of MK-1406 (CD388) by subcutaneous (SC) injection.
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo by SC injection.
Interventions
- Produit combiné MK-1406
MK-1406 liquid for injection administered subcutaneously (SC)
- Produit combiné Placebo
MK-1406 matched liquid for SC injection
Critères de jugement
Critère de jugement principal
Number of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of participants experiencing protocol-defined ILI occurring after administration of MK-1406 (CD388), with influenza infection confirmed by an RT-PCR+ result based on a NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.
Délai Up to approximately 24 weeks post dose
Critère de jugement secondaire
Number of participants with ≥1 Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with ≥1 AE will be assessed.
Délai Up to approximately Day 197
Critère de jugement secondaire
Number of Participants Who Discontinued from the Study Due to an AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued the study because of an AE will be assessed.
Délai Up to approximately Day 197
Critère de jugement secondaire
Number of Participants with Injection Site Reactions (ISRs)
Participants will complete the injection site reaction questionnaire in the eDiary Day 1 through Day 8 following the study intervention administration to assess for reactogenicity, based on the US Food and Drug Administration (FDA) toxicity grading scale used for vaccine trials. Injection site reactions are graded on a scale from 1 to 5 where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe and Grade 4 is potentially life threatening. The injection-site reactions assessed are pain, tenderness, erythema/redness, and induration/swelling.
Délai Up to approximately Day 8 post dose
Critère de jugement secondaire
Number of Stratum B Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of Stratum B ((immunocompromised participants) experiencing protocol-defined ILI occurring after administration of CD388, with influenza infection confirmed by an RT-PCR+ result based on an NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.
Délai Up to approximately 24 weeks post dose
Critère de jugement secondaire
Number of Participants with All-cause Hospitalization within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza
Hospitalizations are defined as an overnight admission in a hospital or similar acute care facility, including emergency rooms due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration. Number of participants with all-cause hospitalization within 30 days after the onset of symptomatic influenza will be assessed.
Délai Up to 30 days after onset of symptomatic laboratory-confirmed influenza
Critère de jugement secondaire
Number of Participants with All-cause Mortality within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza
Number of participants with mortality due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration will be determined.
Délai Up to 30 days after onset of symptomatic laboratory-confirmed influenza
Critère de jugement secondaire
Plasma Concentrations Following Administration of MK-1406 (CD388)
Blood samples will be collected at multiple time points to assess the plasma concentrations of MK-1406.
Délai Day 1 (pre-dose), Day 29, and Day 197 post dose
Critère de jugement secondaire
Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADAs)
The number of participants with confirmed anti MK-1406 antibodies post-baseline (i.e. treatment-emergent ADAs) will be determined via evaluation of blood samples collected at multiple time points.
Délai Day 1 (pre-dose), Day 29, and Day 197 post dose
Critère de jugement secondaire
Number of Participants with Treatment Boosted ADAs
The number of participants with an increase in ADA titer over an initial positive baseline titer (i.e., treatment-boosted ADAs) will be determined will be determined via evaluation of blood samples collected at multiple time points.
Délai Day 1 (pre-dose), Day 29, and Day 197 post dose
Dates
| Date de début | 25 septembre 2025 (réelle) |
|---|---|
| Achèvement principal | 2 juillet 2027 (estimée) |
| Achèvement | 2 juillet 2027 (estimée) |
| Première publication | 8 septembre 2025 (réelle) |
| Dernière mise à jour | 17 novembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | novembre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
93 sites sont en recrutement
Argentina
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| CINME - Centro de Investigaciones Metabólicas ( Site 0007) | Buenos Aires | Buenos Aires F.D. | Actif, sans recrutement |
| Centro de Estudios Infectológicos S.A. ( Site 0002) | CABA | Buenos Aires | Actif, sans recrutement |
| Equipo Ciencia ( Site 0008) | Ciudad Autonoma de Buenos Aires | Buenos Aires | Actif, sans recrutement |
| Sanatorio Mayo Privado S.A ( Site 0003) | Córdoba | Córdoba Province | Actif, sans recrutement |
| Centro Medico de Enfermedades Respiratorias ( Site 0005) | Florida | Buenos Aires | Actif, sans recrutement |
| Instituto del Buen Aire ( Site 0006) | Santa Fe | Actif, sans recrutement |
Australia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Emeritus Research ( Site 0106) | Botany | New South Wales | Actif, sans recrutement |
| Core Research Group ( Site 0102) | Brisbane | Queensland | Actif, sans recrutement |
| Emeritus Research ( Site 0101) | Camberwell | Victoria | Actif, sans recrutement |
| Australian Clinical Research Network ( Site 0103) | Maroubra | New South Wales | Actif, sans recrutement |
| The AIM Centre Hunter Diabetes Centre ( Site 0105) | Newcastle | New South Wales | Actif, sans recrutement |
| Momentum St Leonards ( Site 0107) | St Leonards | New South Wales | Actif, sans recrutement |
| Momentum Clinical Research Taringa ( Site 0104) | Taringa | Queensland | Actif, sans recrutement |
Japan
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Takeuchi Hospital ( Site 0818) | Arakawa City | Tokyo | En recrutement |
| Ishikawa Prefectural Central Hospital ( Site 0814) | Kanazawa | Ishikawa-ken | En recrutement |
| Medical Corporation Chiyukai Shin Komonji Hospital ( Site 0820) | Kitakyushu | Fukuoka | En recrutement |
| National Hospital Organization Tokyo National Hospital ( Site 0802) | Kiyose | Tokyo | En recrutement |
| National Hospital Organization Kumamoto Medical Center ( Site 0801) | Kumamoto | En recrutement | |
| Jobu Hospital for Respiratory Diseases ( Site 0821) | Maebashi | Gunma | En recrutement |
| Maebashi Hirosegawa Clinic ( Site 0804) | Maebashi | Gunma | En recrutement |
| National Hospital Organization Tokyo Medical Center ( Site 0807) | Meguro City | Tokyo | En recrutement |
| Association of Healthcare Corporation Oyama East Clinic ( Site 0823) | Oyama | Tochigi | En recrutement |
| NewHeart Watanabe Institute ( Site 0811) | Suginami | Tokyo | En recrutement |
South Africa
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Josha Research ( Site 0216) | Bloemfontein | Free State | Actif, sans recrutement |
| Madibeng Centre for Research ( Site 0201) | Brits | North West | Actif, sans recrutement |
| TREAD Research ( Site 0206) | Cape Town | Western Cape | Actif, sans recrutement |
| TASK Applied Science - Headquarter ( Site 0211) | Cape Town | Western Cape | Actif, sans recrutement |
| Tiervlei Trial Centre ( Site 0204) | Cape Town | Western Cape | Actif, sans recrutement |
| Centre for the Aids Programme of Research in South Africa. CAPRISA ( Site 0220) | Durban | KwaZulu-Natal | Actif, sans recrutement |
| Synergy Biomed Research Institute ( Site 0218) | East London | Eastern Cape | Actif, sans recrutement |
| Ubuntu Clinical Research Center ( Site 0208) | Johannesburg | Gauteng | Actif, sans recrutement |
| Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0205) | Johannesburg | Gauteng | Actif, sans recrutement |
| Qhakaza Mbokodo Research Clinic ( Site 0215) | Ladysmith | KwaZulu-Natal | Actif, sans recrutement |
| Newtown Clinical Research Centre ( Site 0207) | Newtown | Gauteng | Actif, sans recrutement |
| Paarl Research Centre ( Site 0213) | Paarl | Western Cape | Actif, sans recrutement |
| Jose Pearson TB Hospital ( Site 0202) | Port Elizabeth | Eastern Cape | Actif, sans recrutement |
| Global Clinical Trials ( Site 0212) | Pretoria | Gauteng | Actif, sans recrutement |
| Emmed Research Incorporating ( Site 0209) | Pretoria | Gauteng | Actif, sans recrutement |
| Jongaie Research ( Site 0214) | Pretoria West | Gauteng | Actif, sans recrutement |
| Aurum Institute - Rustenburg ( Site 0203) | Rustenburg | North West | Actif, sans recrutement |
| Welkom Clinical Trial Centre ( Site 0219) | Welkom | Free State | Actif, sans recrutement |
United Kingdom
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Aberdeen Royal Infirmary ( Site 0423) | Aberdeen | Aberdeen City | En recrutement |
| Birmingham Heartlands Hospital ( Site 0440) | Birmingham | En recrutement | |
| Queen Elizabeth Hospital ( Site 0411) | Birmingham | Actif, sans recrutement | |
| Layton Medical Centre ( Site 0405) | Blackpool | Lancashire | En recrutement |
| Bradford Royal Infirmary ( Site 0444) | Bradford | En recrutement | |
| Royal Sussex County Hospital ( Site 0443) | Brighton | Brighton And Hove | En recrutement |
| Southmead Hospital ( Site 0409) | Bristol | Bristol, City of | Actif, sans recrutement |
| Velocity Clinical Research, Bristol ( Site 0428) | Bristol | Bristol, City of | En recrutement |
| University Hospital of Wales ( Site 0420) | Cardiff | Wales | Actif, sans recrutement |
161 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 13 novembre 2026
Date d'achèvement reportée
Primary completion delayed 2 days
2027-06-302027-07-02
- 6 novembre 2026
Site ajouté
26 sites added (211 total)
185211
- 27 octobre 2026
Site ajouté
4 sites added (185 total)
181185
- 15 octobre 2026
Site retiré
181 sites removed (181 total)
362181
- 15 octobre 2026
Statut modifié
Status changed from Active not recruiting to Recruiting
ACTIVE_NOT_RECRUITINGRECRUITING
- 15 octobre 2026
Recrutement ouvert
Recruitment opened
ACTIVE_NOT_RECRUITINGRECRUITING
- 17 septembre 2026
Date d'achèvement reportée
Primary completion delayed 29 days
2027-06-012027-06-30
- 17 septembre 2026
Site ajouté
181 sites added (362 total)
181362